Leslie G. Cleland

Nursing · Health Sciences

48h-index8.6kcitations193works6.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fatty Acid Research and Health(56), Inflammatory mediators and NSAID effects(37), Eicosanoids and Hypertension Pharmacology(37), Rheumatoid Arthritis Research and Therapies(26), Cholesterol and Lipid Metabolism(19)

Publications193 total

The Eating Disorders Genetics Initiative (EDGI): study protocol
UNC Libraries·2024· 6 citedOpen Access
Precision Medicine With Leflunomide: Consideration of the <i>DHODH</i> Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis
Arthritis Care & Research·2020· 10 cited
Retraction: Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis.
Journal of Biological Chemistry·2018Open Access
Fish oil benefits: flawed intelligence on toxins of mass consumption
2017
Disease activity trajectories in early rheumatoid arthritis following intensive <scp>DMARD</scp> therapy over 3 years: association with persistence to therapy
International Journal of Rheumatic Diseases·2017· 14 cited
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis.
Journal of Biological Chemistry·2017· 44 citedOpen Access
Contributors
Elsevier eBooks·2016
Nutrition and Rheumatic Diseases
Elsevier eBooks·2016
Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort
The Journal of Rheumatology·2016· 13 cited
The <i>PTPN22</i> gene is associated with idiopathic inflammatory myopathy
Muscle & Nerve·2016· 2 cited
Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?
International Journal of Clinical Practice·2016· 2 cited
Specialised pro-resolving mediators of inflammation in inflammatory arthritis
Prostaglandins Leukotrienes and Essential Fatty Acids·2016· 122 cited
Ten years of publicly funded biological disease‐modifying antirheumatic drugs in Australia
The Medical Journal of Australia·2016· 18 cited
Medicinal Fatty Acids
Compendium of Inflammatory Diseases·2016
Determining the acceptable level of physician compliance with a treat‐to‐target strategy in early rheumatoid arthritis
International Journal of Rheumatic Diseases·2015· 8 cited
Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial
Osteoporosis International·2015· 26 cited
Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose
Annals of the Rheumatic Diseases·2015· 141 citedOpen Access
Plasma <i>n</i>-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis
British Journal Of Nutrition·2015· 32 citedOpen Access
Synovial fluid and plasma n3 long chain polyunsaturated fatty acids in patients with inflammatory arthritis
Prostaglandins Leukotrienes and Essential Fatty Acids·2015· 13 cited
Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years
Arthritis Research & Therapy·2015· 27 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Michael J. James(31), Susanna Proudman(9), Robert A. Gibson(8), Gillian E. Caughey(7), Robert G. Metcalf(7), W H Betts(5), Glenn D. Young(4), Maureen Rischmueller(4), Catherine Hill(4), Marc Pouliot(4), Jennifer R. Gamble(3), Robert Stuklis(3), Thomas Sullivan(3), Lisa K. Stamp(3), Prashanthan Sanders(3), Susan Lester(3), Peter S. Penglis(2), Evangeline Mantzioris(2), Mark A. Neumann(2), Maryanne Demasi(2)